Leland Stanford Junior University

Kosan Biosciences Incorporated

Other

The John Innes Institute

Brown University

Alvine Pharmaceuticals, Inc.

Washington University

The John Innes Centre

Celiac Sprue Research Foundation

Kosam Biosciences, Inc.

Kason Biosciences, Inc.

The Johns Innes Institute

Chaitan Khosla

Camilla M Kao

Robert G McDaniel

David A Hopwood

Lu Shan

Hong Fu

Suzanne Ebert-Khosla

Guanglin Luo

Leonard Katz

Bryan Julien

Rembert Pieper

David E Cane

Gary Gray

Daniel V Santi

Li Tang

Felix Hausch

Daniel T Chu

Rainer Ziermann

Christopher Reeves

Michael Thomas Bethune

Matthew John Siegel

Gary W Ashley

Kai Wu

Kihang Choi

Jonathan David Gass

Richard Edward Watts

Susanne Ebert-Khosla

Andreas W Schirmer

Maria Fardis

Daniel Meron Pinkas

Peter J Licari

John R Carney

Rajesh Sudhir Gokhale

Janice Lau

Nicola L Pohl

Stuart Tsuji

Gail G Pyle

Keith M Rich

Yandong Li

David C Myles

Yan Zhu

James Francis McIntire

Ralph C Reid

Michael A Siani

Indu Isaacs

Yong Li

Michael C Bassik

Ayse Okesli

Pawan Kumar

Robert Caren

Zhihao Hu

Thomas Marti

Akihiko Fujie

Thomas DiRaimondo

Blaine Pfeifer

Art Salomon

Chu-Young Kim

Hanne Quarsten

Ludvig M Sollid

Jiang Xia

Justin L Piper

Richard Deans

David Morgens

Harmit Vora

Gregg Strohmeier

Xirui Xiao

Cornelius Kloeck

Compounds and methods are provided for the treatment of pathogenic virus infections or cancer. The formulations combine an inhibitor of de novo pyrimidine synthesis, and an inhibitor of a pyrimidine salvage pathway enzyme.

Use of a DHODH inhibitor in combination with an inhibitor of pyrimidine salvage

Provided herein include methods and compositions for synthesis of Lipid IVand derivatives thereof, using a defined set of pathway enzyme, which may be isolated and used to reconstitute all or part of the pathway in a cell-free reaction.

Defined enzymatic synthesis of lipid A analogs

Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activity of TG2 associated with inflammatory disorders, which disorders may include, without limitation, sepsis, ischemic reperfusion injury, renal fibrosis, and the like.

Modulation of tissue transglutaminase activation in disease

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Enzyme treatment of foodstuffs for celiac sprue

Transglutaminase inhibitors and methods of use thereof are provided.

Transglutaminase inhibitors and methods of use thereof

A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.

Combination enzyme therapy for digestion of dietary gluten

The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

Biomarker to measure drug efficacy in enteropathic disease

Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue.

Diagnostic method for celiac sprue

Methods are provided for the production of gram to kilogram quantities of pro-EP-B2 (proenzyme form of EP-B2) in a lyophilized form. The methods include scalable fermentation, refolding and purification processes, which processes may be combined with lyophilization to yield a stable product.

Scaleable manufacturing process for cysteine endoprotease B, isoform 2

Compounds according to formula I wherein m is 0 or 1;X is and R, R, RR, and Rare as defined herein, are useful as anti-infective agents.

Ketolide anti-infective compounds

Growing community of inventors

Palo Alto, CA, United States of America

Chaitan Khosla